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admission. Tissue Doppler Echo was done at admission and 12
hours, 24 hours, 36 hours and 72 hours and 96 hrs after PCI. The
PCI was successful with TIMI 3 flow in 98 % of cases. 35 cases
required IABP support. The mortality at 72 hours was 32 % (13 out
of 40 cases). 50 % of cases remained in LVF at 96 hrs. Patients with
valvular stenosis were excluded from study. Parameters assessed
were global ejection fraction , regional wall motion changes, valve
regurgitation, TVI based velocity gradient with segmental TT plot,
, septal to lateral wall delay, regional strain rate evaluation with
CAMMplot and “Bullet”map , Dp/dtmeasurement usingMR jet, e/
e' ratio to assess LA pressures and myocardial performance index
measurements (Tei Index) . Baseline EF was 18-38 % (average 24
%), E/E' Ratios 12-18 (average 15), dp/dt 1100-840 (average 980) and
Tei index 0.37- 0. 66 (average 0.55) . Survival at 30 days was 60 %.
Results: Post PCI The patients who were not in LVF or low Cardiac
output had significantly improved dp/dt values (p <0.01),
improved Tei index (p<0.01), improved global EF (p<0.01) and
improved segmental TVI based TT plots and strain rate values
(p>0.001). Also all patients who showed recovery from LVF or
shock had improved Tissue Doppler parameters at 36 hrs with no
late improvement at 96 hrs.
Conclusion: Tissue Doppler parameters can be a good guide to
assess recovery from PCI after acutemyocardial infarction (Killip 3
or 4). Early recovery of tissue Doppler parameters at 36 hrs seems
to predict eventual recovery. Also tissue Doppler may be used as a
routine tool in the coronary care unit tomonitor sick patients after
Acute MI.
An analysis of the risk factor profile of patients of
established coronary artery disease
Vikas Singh, Pramod Kumar, Ajay Kr Sinha
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Background: A knowledge of the risk factors of CAD which are
modifiable plays an important role in its control. A few population
based studies are available from different parts of the world. Since
risk factors tend to be different in different geographical areas, the
same information cannot be extrapolated everywhere and the
need for the present study.
Method: A retrospective analysis of all the coronary angiography
cases done at our centre beween Jan 1, 2014 to July 15, 2014 was
done with respect to the risk factor profile of the patients. Those
with normal epicardial coronaries were excluded from the study.
Results: A total of 668 coronary angiographies were done at our
centre during the specified period. 65 of these came out normal
and were excluded from the study. A single risk factor was seen in
261 patients (43.2%). 2 or more risk factors were seen in 39% of the
patient population while 17.9% of the patients had no risk factor.
Analysis of dyslipidemia was not made in our study. Amongst
those with a single risk factor; hypertension was the most com-
mon (22.4% of patients) followed by 10.4% each of diabetes mel-
litus and tobacco use in any form.
Overall, diabetes mellitus was seen in 41.7% of this patient
population and hypertension in 56.7% in our part. Tobacco con-
sumption was seen in 35.8% of the patient population.
Conclusion: More than 80% of patients with established CAD had
presence of one or more risk factor of CAD; however in 18% no
conventional risk factor of CAD could be identified further
strengthening the notion that CAD is the result of a complex
interplay of genetic and environmental factors. Hypertension was
the single commonest risk factor followed by diabetes. Tobacco in
one or the other form contributed in around 36% of population,
highlighting the need to curb down the usage and make strong
law against its availability.
Diagnostic utility of heart-type fatty acid binding
protein in patients with acute coronary syndrome
Rajiv Bajaj, Brijesh Shrivastava
Batra Hospital and Medical Research Centre, New Delhi, India
Background: Heart-type fatty acid-binding protein (H-FABP) is a
sensitive biomarker for myocardial infarction and can be detec-
ted in blood within one to three hours of the pain. The objective
of the study was to study diagnostic utility of H-FABP in acute
coronary syndromes and its sensitivity and specificity in
different patients subgroups varying with respect to duration of
symptoms.
Methods: From May 2012 to August 2013, patients more than 18
yrs of age presented to cardiac emergency and admitted to the
Department of cardiology, in our hospital with acute ischemic
type of chest pain of less than 8 hrs of duration were eligible for
enrolment in this prospective study.
50 patients were enrolled for the study and classified in 3 clinical
subgroups
Results: Group A comprised of 20 patients presented with acute
chest pain between 20 min to 2 hrs of duration. In this group 10
patients showed positive H-FABP and one patient showed both
positive CK-MB and troponin I. The sensitivity found to be 100 %(
95% CI-5.5 to 100%).The specificity of H-FABP was 52.6 %( 95% CI-
29.5-74.8%).
Group B comprised of 20 patients who presented more than 2
hrs and up to 8 hrs since symptom onset with or without ECG
changes and troponins may or may not be negative. In group B 17
patients showed Positive H-FABP test, 10 had elevated CK-MB and
14 had elevated Troponin I. The sensitivity of H-FABP for detecting
MI as compared to initial CK-MBwas found to be 90% (95% CI-54.1-
99.5) and Specificity was 20% (95% CI-3.5-55.8).Positive predictive
value was 52.9% (95% CI-28.5-76.1) and Negative predictive Value
was 66.7% (95%CI - 12.5-98.2).
Group C had 10 patients who presented with chest pain of
duration between 2 hrs to 4 hrs, but had ECG changes confounding
the diagnosis of MI (e.g. LBBB, pacemaker rhythm). H-FABP was
positive in 6 (12%) of patients and Troponin I was elevated in 1
patient and none had elevated CK-MB level for diagnosis of MI. As
compared to initial Troponin I values sensitivity was 100 % (with
95% of CI-5.5 to 100%), Specificity was 44.4 % (95% CI-15.3-77.4),
Positive predictive value of 16.7% and Negative predictive value of
100% (95% CI- 39.6-100).
Conclusion: Measuring H-FABP in addition to cTnI and CK-MB at
the time of admission with acute ischaemic chest pain will assist
in the early diagnosis of acute MI. Using a combined approach
improves sensitivity further for these patients.
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Background: The TIMI frame count (TFC) has been proposed as a
method to assess coronary blood flow. The TFC reflects coronary
flow reserve. Cardiac hypertrophy is associated with a decrease in
coronary reserve. Several factors have been shown to relate with
TFC, but the relation between left ventricular hypertrophy (LVH)
and TFC has not yet been investigated.
Aims and objectives: To determine whether LVH affects TFC.
Materials and Methods: The TFC was measured in 200 subjects
without history of myocardial infarction and significant coronary
stenosis. Determination of left ventricular mass index (LVMI) ac-
cording to the formula of Devereux was performed, and LVH was
defined by LVMI >134 g/m2 in men and >110 g/m2 in women. The
patients were divided into 2 groups according to presence of LVH:
group 1 with LVH (n ¼ 16; aged 51 ± 11 years; 8 women), and group
2 without LVH (n ¼ 18; aged 50 ±8 years; 8 women).
Results: The mean TFC in the right coronary artery (RCA) was
significantly higher in group1 (24,1 ±4,9 frames) than in group 2
(20,9 ±5,4 frames, p ¼ 0.01). The TFC in the RCA was significantly
correlated with interventricular septum thickness (r ¼ 0,36; p ¼
0,004) and left ventricular posterior wall thickness (r ¼ 0,33; p ¼
0,007), but not with LVMI (r ¼ 0.18; p ¼ 0.17). The mean TFC in the
left anterior descending (LAD) and left circumflex (Cx) arteries
were not different between the two groups. No correlation existed
between TFC in the LAD or LCx and echocardiographic
parameters.
Conclusions: Left ventricular hypertrophy has significant effect
on the TFC in the RCA but not in LAD and LCX. Therefore, studies
comparing TFC need to consider LVH.
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Background: Antiplatelet therapy with platelet P2Y12 receptor
antagonists is a cornerstone of antithrombotic treatment in pa-
tients. Since the data is largely derived from clinical trials, the
TREASURE observational study is designed to address the need to
understand the usage pattern of Ticagrelor in real life scenario in
large number of ACS patients in India. To our knowledge, it will be
largest ever antiplatelet agent related observational study in real
world scenario in India.
Objectives: To describe the usage pattern of Ticagrelor in various
ACS patient population who undergo either PCI, CABG or medical
management in a real-life setting from 60 different centers in
India.
Methods: This is an observational, multi-centric, prospective
study. Study proposes to include 3000 subjects from 60 centres
across India. Key inclusion Criteria would be provision of subject
informed consent and Patients who had been hospitalized for ACS
and are on ticagrelor on discharge or on Ticagrelor therapy for 
1month will be enrolled in the study and followed up for a period
of 12 months. Demographic data, Diagnosis (type of ACS), Man-
agement of ACS, Laboratory Investigations, relevant history,
physical examination will be collated.
Results: Study is expected to fill a significant gap exists in our
knowledge to understand the usage pattern of Ticagrelor in real
life scenario in large number of ACS patients in India. The aim of
this national study is to understand the usage pattern (including
the duration of treatment) of Ticagrelor in various ACS patient
population undergoing PCI, CABG or medical management in a
real-life setting in India.
Moreover, patients with various risk factors [i.e. elderly pa-
tients, diabetes, renal impairment, smoking, GRACE risk score)
and their association with ACS and Ticagrelor usage will be
measured. Study also intends to record any clinical event (CV
event, Bleeding etc) during the follow up period of the study.
Conclusion: The multicenter national study will allow generating
real life evidence by involving patients from different geographies
and healthcare systems in India. The study is intended to provide
useful evidence of the ticagrelor usage in variety of ACS patients
in actual hospital settings. Along with the PLATO study result; this
data will be extremely useful to optimize ACS management in
India in order to save more lives.
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Background: Primary percutaneous coronary intervention (PCI)
is the treatment of choice for patients presenting with acute ST-
segment elevation myocardial infarction (STEMI). However, if
catheterization facilities are not immediately available (e.g.
countries like India) the effectiveness of PCI can be affected by
delays in transfer. Evidence suggests that antiplatelet therapy
administered early, preferably in the ambulance during transfer,
may provide better and earlier perfusion. Ticagrelor, a direct
platelet P2Y12 receptor inhibitor, is indicated for themanagement
of patients with acute coronary syndromes. In India, a large scale
Kerala ACS registry, found big time delay between ACS (Acute
Coronary Patients) symptom and PCI. In this scenario, it was
important to evaluate implications of ATLANTIC (Administration
of Ticagrelor in the cath Lab or in the Ambulance for New ST
elevation myocardial Infarction to open the Coronary artery)
study in Indian scenario. This analysis is imperative in the view of
the fact that the latest European Society of Cardiology (ESC) 2014
myocardial revascularization guidelines recommended P2Y12
inhibitors to be given at first medical context for patient under-
going primary PCI.
Aim: To evaluate whether earlier, in-ambulance or administration
of Ticagrelor could safely improve coronary reperfusion in pa-
tients with STEMI transferred for PCI.
Methods: ATLANTIC is an international,multicenter, randomized,
double-blind study involving 1862 patients with ongoing STEMI of
less than 6 hours duration, comparing pre-hospital (in the
ambulance) versus in-hospital (in the catheterization laboratory)
treatment with Ticagrelor. The co-primary end points were the
proportion of patients who did not have a 70% or greater resolu-
tion of ST-segment elevation before percutaneous coronary
intervention (PCI) and the proportion of patients who did not have
Thrombolysis in Myocardial Infarction flow grade 3 in the infarct-
related artery at initial angiography. Secondary end points
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